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Figure S1, related to Figure 1. Memory B cell subsets and their response after 1 
heterologous challenge.  2 
(A) Validation of WNV WT DIII tetramers by analyzing the swIg (IgM-IgD-) MBC 3 
compartment after WNV vaccination. (B) Gating strategy for MBC subsets based on 4 
CD80 and CCR6 expression. Cells are gated on CD19+GL7- and IgM+IgD+, IgM+IgD-, or 5 
swIg expression. Concatenated data from one experiment is shown. (C) Validation of 6 
JEV ESAK DIII by ELISA. JEV DIII-LR specific mAb JEV-31 (Fernandez et al., 2018) 7 
was used to confirm loss of the LR epitope. Wild-type mice were immunized with JEV 8 
ESAK DIII, and immune serum was used to probe for binding to JEV WT and ESAK 9 
DIII. Data from 1 experiment is shown. Mean values ± SEM are shown. (D) Serum from 10 
WNV-immune mice before (d0) and 14 days after JEV vaccination was assessed for 11 
antibody binding to WNV WT DIII, WNV KT DIII, and JEV WT DIII. Data pooled from 12 
one experiment with 3 mice, and correspond with Figure 1D. **** , p< 0.0001 by 2-way 13 
ANOVA. (E) Enrichment of WNV DIII-specificity in different MBC subsets >8 weeks after 14 
WNV infection. (F) Frequency of WNV DIII-specific GC B cells 2 weeks after JEV 15 
vaccination of WNV infected mice.  16 
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Figure S2, related to Figure 2. Validation of Aicda f/f mice.  19 
(A) Targeting construct for Aicda. (B) PCR genotyping of the Aicda allele to confirm 20 
targeting and absence of neomycin resistance cassette. (C) Aicdaf/f x TamCre mice 21 
were immunized with sheep red blood cells and treated with tamoxifen starting on day 7 22 
after immunization. CD19+GL7+ cells were sorted at different days after tamoxifen and 23 
immunoblotted for AID. ERK2 level (probed with anti-ERK2 antibody) was used as the 24 
loading control. (D) Aicdaf/f x TamCre mice were treated with tamoxifen for two weeks 25 
and then immunized with the inactivated WNV vaccine. Serum was collected 12 days 26 
later to confirm absence of anti-WNV WT DIII IgG antibodies. Mean values ± SEM are 27 
shown.  28 
 29 
































































































log10 (serum dilution factor)







































































pre-JEV d28 post-JEV 
3 
 
Figure S3, related to Figure 2. IgM responses after heterologous JEV vaccination.  31 
(A) Schematic representation of the experimental setup for ZIKV DIII immunization and 32 
subsequent JEV recall responses. (B) Serum from ZIKV DIII-immunized AID cKO and 33 
AID WT was collected before and 28 days after JEV vaccination. IgG serum antibody 34 
binding to ZIKV WT DIII, JEV WT DIII, and JEV ESAK DIII at different serum dilutions 35 
was assessed by ELISA. Data are pooled from two independent experiment with 5-6 36 
mice per genotype for each experiment. Mean values ± SEM are shown. (C) Schematic 37 
representation of DENV and ZIKV recall responses. (D) The frequency of ZIKV DIII-38 
specific MBCs and LLPCs were quantified by flow cytometry and ELISPOT, 39 
respectively. Mice challenged with only ZIKV (1) were used to delineate the naïve B 40 
cell responses. AID WT (2 only) is calculated by subtracting the average WT primary 41 
response value (1) from the AID WT (1 and 2) values. Mean values ± SEM are 42 
shown; each symbol represents one mouse. Data are pooled from two independent 43 


































































































































































































KD,kinetics (M) = 5.3 x 10-8


























































ka(1/Ms) = 4.02 x 105 KD,kinetics (M) = 1.7 x 10-8
kd(1/s) = 7 x 10-3 KD,equil. (M)  = 1.5 x 10-8
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Figure S4, related to Figure 4. Isolation of mAbs from MBCs and LLPCs.  50 
 (A) Gating strategy for WNV DIII-specific LLPCs. LLPCs were first assessed for surface 51 
B cell receptor expression by analyzing surface kappa expression. LLPCs in the bone 52 
marrow were enriched for CD138 expression followed by WNV WT DIII staining with 53 
two different tetramers. (B) Wild-type mice were immunized with inactivated WNV 54 
vaccine, and DIII-specific MBCs and LLPCs were sorted at least 8 weeks after 55 
vaccination. Gating strategy for CD19+GL7- WNV DIII-specific MBCs. Splenocytes were 56 
depleted of CD3, CD4, CD8, CD11b, Ter119, IgM and IgG prior to sorting. (C) Reverse 57 
orientation ELISA of a subset of DIII-specific mAbs to measure monovalent affinities. 58 
ELISA plates were coated with a fixed concentration of mAbs and incubated with 59 
increasing concentrations of WNV WT DIII. Mean values ± SEM are shown. (D) 60 
Example binding curve (left) generated by biolayer interferometry with increasing 61 
concentrations of WNV WT DIII. Binding curves were fit to a 1:1 binding model using 62 
ForteBio’s analysis software. The panel to the right of the binding curve shows steady-63 
state analysis results (KD, equilibrium), plotted as the binding response (nm) versus 64 
concentration of DIII, shows binding saturation. A Scatchard plot, shown in the inset in 65 
the steady-state analysis panel, suggests single binding affinity. The binding association 66 
(middle right) and dissociation (right) constants were calculated. Mean ± SEM are 67 
shown; each symbol represents one mAb. 68 
 69 
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Figure S5, related to Figure 5. Deletion of AID during GC reactions does not 71 
impair class switching or differentiation of MBCs and LLPCs.  72 
(A) Frequencies of isotype switched (IgM-IgD-), WNV DIII+ GC B cells (CD19+GL7+) 7 73 
and 14 days after immunization of wild-type mice with inactivated WNV vaccine as 74 
measured by flow cytometry. Mean values ± SEM are shown. Each symbol represents 75 
one mouse. Data are pooled from two independent experiments. (B) WT mice were 76 
immunized with inactivated WNV vaccine. WNV DIII+ GC B cells (CD19+GL7+IgD-) were 77 
sorted at different time points and IgH repertoire analysis was performed by MiSeq. The 78 
total number of replacement mutations for IgH is shown for each week. (C) WT mice 79 
were immunized with inactivated WNV vaccine, and the number of DIII-specific bone 80 
marrow plasma cells were enumerated by ELISPOT at different time points. 81 
Representative wells are shown on the left and quantified on the right. Mean values ± 82 
SEM are shown. Each symbol represents one mouse. Data are pooled from two 83 
independent experiments. (D) Schematic of experiments to test for Cre toxicity. Sera 84 
were collected 28 days after vaccination and probed for anti-WNV WT DIII and E protein 85 
IgG antibodies. Mean values ± SEM are shown. (E) WNV DIII-specific LLPC numbers 86 
after WNV vaccination and AID deletion were enumerated by ELISPOT. Mean values ± 87 
SEM are shown. Each symbol represents one mouse. Data are pooled from two 88 
independent experiments. (F) Serum from mice after WNV vaccination and AID deletion 89 
was collected 8 weeks post-immunization, and IgM antibodies were probed for WNV E 90 
reactivity by ELISA. Mean values ± SEM are shown. Data are pooled from two 91 
independent experiments.  92 

































































































































































































































































































































































Figure S6, related to Figure 6. WNV DIII-LR and WNV DIII non-LR naïve and 94 
precursor cells are not selected from distinct B cell subsets.  95 
(A) WT mice were immunized with inactivated WNV vaccine. WNV DIII+ MBCs 96 
(CD19+GL7-IgD-IgM-CD80+CCR6+) and WNV DIII+ bone marrow PCs (CD138hiIgM-) 97 
were sorted at different time points and IgG repertoire analysis was performed by 98 
MiSeq. The total number of replacement mutations for IgH is shown for each week. 99 
Mean ± SEM are shown. ****p < 0.0001; Kruskal-Wallis test. (B) The number of silent 100 
and total mutations in the heavy and light chains of the isolated panels of mAbs are 101 
plotted. Mean ± SEM are shown; each symbol represents one mAb. *p < 0.05; Mann-102 
Whitney test. (C) The number of replacement, silent, and total mutations found in DIII-103 
LR and DIII non-LR specific mAbs from the MBC compartment. (D) ELISA binding 104 
curves for WNV SVPs are compared for germline-reverted and somatically-mutated 105 
mAbs from MBCs and LLPCs. Mean ± SEM are shown. Mean ± SEM are shown. ****p 106 
< 0.0001; two-way ANOVA. (E) Spleens from naïve mice were enriched for WNV WT 107 
and KT DIII tetramers binding. Frequencies of antigen-specific cells in the follicular 108 
(FoB) and marginal zone (MZ) B cell compartments were enumerated by flow 109 
cytometry. A representative flow cytometry plot is shown on the left and quantified on 110 
the right. Mean values ± SEM are shown. (F) Frequencies of WNV DIII-LR and WNV 111 
DIII non-LR-specific cells in Hardy Fractions E (Fr. E) and F (Fr. F) were enumerated by 112 
flow cytometry. A representative plot is on the left and quantification is shown in the 113 
middle. The IgM geometric mean fluorescence intensities (gMFI) of WNV DIII-LR and 114 
WNV DIII-non LR specific cells in Hardy Fractions E and F are quantified on the right. 115 
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Figure S7, related to Figure 7. Single cell RNA sequencing and lineage tracing 117 
validation.  118 
(A) MBC precursor cells in polyclonal GC B cells (CD19+GL7+IgD-) were identified using 119 
CD38, EfnB1, and CCR6 as markers. Example gating strategy to identify the MBC 120 
precursors is shown on the left and frequencies were quantified on the right. Mean ± 121 
SEM are shown. Data are from one experiment where each symbol represents one 122 
mouse. ****p < 0.0001; two-way ANOVA. (B) UMAP plots indicating cell cycle stage for 123 
each cluster (top) and Klf2 gene expression (bottom). (C) Polyclonal swIg CD80+CCR6+ 124 
MBCs were sorted from wild-type mice vaccinated with WNV one week prior. scRNA 125 
profiles of mature GC B cells (as in Figure 7A) with the sorted MBCs (left) and 126 
computed MBC module score (right). (D) UMAP plot displaying Cd38 and Ccr6 gene 127 
expression levels in individual cells. (E) Clonal overlap between DIII-specific MBC 128 
precursors, DIII-specific GC B cells, and polyclonal MBCs are displayed as links 129 
between all three populations. (F) Jchain expression in GC B cells was confirmed by 130 
crossing Jchain to LSL-TdTomato mice and administering tamoxifen for two weeks. 131 
TdTomato expression was quantified for B cells (CD19+ in the spleen or B220+ in the 132 
bone marrow), plasma cells (PC, CD138+), non-B cells (B220-CD138- in bone marrow, 133 
CD19-GL7-CD138- in spleen), and GC B cells (CD19+GL7+). Mean values ± SEM are 134 
shown. (G) Expected results for TdT-Jchain mice if MBCs are committed early and 135 
continue to participate in GCs or if there is continuous selection of MBCs.  136 




Jchain WT_F TGCTGTGCAGATGATTAGG 
Jchain Tg_F CCCACATCAGGCACATGAGTAACAA 
Jchain common_R:  CTCCTTGAGCAGACATGAGGATT 
 
Table S3. Primers used to genotype transgenic mice, related to STAR Methods.   
